AI Opportunities for Life Sciences R&D - with Andrew Bolt of Deloitte

0 Ratings
0
Episode
786 of 969
Duration
29min
Language
English
Format
Category
Economy & Business

Today’s guest is Andrew Bolt, Partner at Deloitte. He joins Emerj CEO and Head of Research Daniel Faggella on today’s podcast to talk about challenges in R&D for life sciences. While productivity has remained stagnant for the last 10-15 years, advances in AI-enhanced protein structure prediction are revolutionizing drug targeting and the very infrastructure of recruiting patients for clinical trials. Later, the two postulate on the ways AI can expedite regulatory compliance in pharmaceutical R&D in similar ways. Find out more about sponsored content and how to engage with the Emerj audience at emerj.com/ad1.


Listen and read

Step into an infinite world of stories

  • Read and listen as much as you want
  • Over 1 million titles
  • Exclusive titles + Storytel Originals
  • 14 days free trial, then €9.99/month
  • Easy to cancel anytime
Try for free
Details page - Device banner - 894x1036

Other podcasts you might like ...